Skip to main content
. 2017 Feb 20;13(4):2583–2590. doi: 10.3892/ol.2017.5753

Figure 2.

Figure 2.

PcG risk-score analysis of 183 patients and validation of the five-PcG signature for survival prediction by the CGGA and GSE16011 set. (A) The prognostic five-PcG signature risk-score distribution. (B) Survival status and time of patients. (C) Heat map of the five-PcG expression profiles. Rows represent PcG genes, and columns represent patients. Overall survival of (D) 183 patients in the CGGA set and (E) 270 patients in the GSE16011 set. PcG, polycomb group; CGGA, Chinese Glioma Genome Atlas; EZH1, enhancer of zeste homolog 1; EZH2, enhancer of zeste homolog 2; DNMT3A, DNA (cytosine-5-)-methyltransferase 3; DNMT3B, DNA (cytosine-5-)-methyltransferase 3α; PHF19, PHD finger protein 19.